- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 787981, 7 pages
Mulberry Leaf Reduces Oxidation and C-Reactive Protein Level in Patients with Mild Dyslipidemia
1Bioactive Resources for Innovative Clinical Applications Research Unit, and Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, PhayaThai Road, Phatumwan, Bangkok 10330, Thailand
2Division of Nephrology, Department of Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok 10400, Thailand
Received 3 October 2012; Revised 17 December 2012; Accepted 31 December 2012
Academic Editor: Joseph Fomusi Ndisang
Copyright © 2013 Pornanong Aramwit et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- T. H. Kang, J. Y. Hur, H. B. Kim, J. H. Ryu, and S. Y. Kim, “Neuroprotective effects of the cyanidin-3-O-beta-d-glucopyranoside isolated from mulberry fruit against cerebral ischemia,” Neuroscience Letters, vol. 391, no. 3, pp. 122–126, 2006.
- M. Y. Park, K. S. Lee, and M. K. Sung, “Effects of dietary mulberry, Korean red ginseng, and banaba on glucose homeostasis in relation to PPAR-α, PPAR-γ, and LPL mRNA expressions,” Life Sciences, vol. 77, no. 26, pp. 3344–3354, 2005.
- P. Aramwit, K. Petcharat, and O. Supasyndh, “Efficacy of mulberry leaf tablets in patients with mild dyslipidemia,” Phytotherapy Research, vol. 25, no. 3, pp. 365–369, 2011.
- B. Enkhmaa, K. Shiwaku, T. Katsube et al., “Mulberry (Morus alba L.) leaves and their major flavonol quercetin 3-(6-malonylglucoside) attenuate atherosclerotic lesion development in LDL receptor-deficient mice,” Journal of Nutrition, vol. 135, no. 4, pp. 729–734, 2005.
- A. Harauma, T. Murayama, K. Ikeyama et al., “Mulberry leaf powder prevents atherosclerosis in apolipoprotein E-deficient mice,” Biochemical and Biophysical Research Communications, vol. 358, no. 3, pp. 751–756, 2007.
- Y. Shibata, N. Kume, H. Arai et al., “Mulberry leaf aqueous fractions inhibit TNF-α-induced nuclear factor κB (NF-κB) activation and lectin-like oxidized LDL receptor-1 (LOX-1) expression in vascular endothelial cells,” Atherosclerosis, vol. 193, no. 1, pp. 20–27, 2007.
- P. Sritara, S. Cheepudomwit, N. Chapman et al., “Twelve-year changes in vascular risk factors and their associations with mortality in a cohort of 3499 Thais: The Electricity Generating Authority of Thailand study,” International Journal of Epidemiology, vol. 32, no. 3, pp. 461–468, 2003.
- P. Tatsanavivat, V. Klungboonkrong, A. Chirawatkul et al., “Prevalence of coronary heart disease and major cardiovascular risk factors in Thailand,” International Journal of Epidemiology, vol. 27, no. 3, pp. 405–409, 1998.
- J. L. Witztum and D. Steinberg, “The oxidative modification hypothesis of atherosclerosis: does it hold for humans?” Trends in Cardiovascular Medicine, vol. 11, no. 3-4, pp. 93–102, 2001.
- J. P. Gaut and J. W. Heinecke, “Mechanisms for oxidizing low-density lipoprotein: insights from patterns of oxidation products in the artery wall and from mouse models of atherosclerosis,” Trends in Cardiovascular Medicine, vol. 11, no. 3-4, pp. 103–112, 2001.
- Y. Ohara, T. E. Peterson, H. S. Sayegh, R. R. Subramanian, J. N. Wilcox, and D. G. Harrison, “Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production,” Circulation, vol. 92, no. 4, pp. 898–903, 1995.
- M. P. Reilly, D. Praticó, N. Delanty et al., “Increased formation of distinct F2 isoprostanes in hypercholesterolemia,” Circulation, vol. 98, no. 25, pp. 2822–2828, 1998.
- D. Steinberg, S. Parthasarathy, T. E. Carew, J. C. Khoo, and J. L. Witztum, “Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity,” The New England Journal of Medicine, vol. 320, no. 14, pp. 915–924, 1989.
- N. Singhania, D. Puri, S. V. Madhu, and S. B. Sharma, “Assessment of oxidative stress and endothelial dysfunction in Asian Indians with type 2 diabetes mellitus with and without macroangiopathy,” QJM, vol. 101, no. 6, pp. 449–455, 2008.
- H. Chen, M. Yu, M. Li et al., “Polymorphic variations in manganese superoxide dismutase (MnSOD), glutathione peroxidase-1 (GPX1), and catalase (CAT) contribute to elevated plasma triglyceride levels in Chinese patients with type 2 diabetes or diabetic cardiovascular disease,” Molecular and Cellular Biochemistry, vol. 363, pp. 185–291, 2012.
- S. Black, I. Kushner, and D. Samols, “C-reactive protein,” Journal of Biological Chemistry, vol. 279, no. 47, pp. 48487–48490, 2004.
- P. Libby and P. M. Ridker, “Inflammation and atherosclerosis: role of C-reactive protein in risk assessment,” American Journal of Medicine, vol. 116, no. 6, pp. 9–16, 2004.
- V. Pasceri, J. T. Willerson, and E. T. H. Yeh, “Direct proinflammatory effect of C-reactive protein on human endothelial cells,” Circulation, vol. 102, no. 18, pp. 2165–2168, 2000.
- N. Rifai, R. P. Tracy, and P. M. Ridker, “Clinical efficacy of an automated high-sensitivity C-reactive protein assay,” Clinical Chemistry, vol. 45, no. 12, pp. 2136–2141, 1999.
- P. M. Ridker, C. H. Hennekens, J. E. Buring, and N. Rifai, “C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women,” The New England Journal of Medicine, vol. 342, no. 12, pp. 836–843, 2000.
- P. M. Ridker, J. E. Buring, N. Rifai, and N. R. Cook, “Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score,” Journal of the American Medical Association, vol. 297, no. 6, pp. 611–619, 2007.
- T. A. Pearson, G. A. Mensah, R. W. Alexander et al., “Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association,” Circulation, vol. 107, no. 3, pp. 499–511, 2003.
- P. M. Ridker, J. MacFadyen, P. Libby, and R. J. Glynn, “Relation of baseline high-sensitivity c-reactive protein level to cardiovascular outcomes with rosuvastatin in the justification for use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER),” American Journal of Cardiology, vol. 106, no. 2, pp. 204–209, 2010.
- M. S. Blois, “Antioxidant determinations by the use of a stable free radical,” Nature, vol. 181, no. 4617, pp. 1199–1200, 1958.
- S. M. Grundy, J. I. Cleeman, C. N. Merz, et al., “Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines,” Circulation, vol. 110, no. 2, pp. 227–239, 2004.
- D. E. Paglia and W. N. Valentine, “Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase,” The Journal of Laboratory and Clinical Medicine, vol. 70, no. 1, pp. 158–169, 1967.
- B. Jacobson, G. Quigley, and G. Lockitch, “Adaptation of glutathione peroxidase assay to the Technicon RA-1000,” Clinical Chemistry, vol. 34, no. 10, pp. 2164–2165, 1988.
- J. Danesh, J. G. Wheeler, G. M. Hirschfield et al., “C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease,” The New England Journal of Medicine, vol. 350, no. 14, pp. 1387–1397, 2004.
- W. Koenig, N. Khuseyinova, J. Baumert et al., “Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 12, pp. 2745–2751, 2006.
- D. M. Lloyd-Jones, K. Liu, L. Tian, and P. Greenland, “Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease,” Annals of Internal Medicine, vol. 145, no. 1, pp. 35–42, 2006.
- B. J. Coventry, M. L. Ashdown, M. A. Quinn, S. N. Markovic, S. L. Yatomi-Clarke, and A. P. Robinson, “CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?” Journal of Translational Medicine, vol. 7, article 102, 2009.
- H. H. Hermsdorff, A. C. Volp, B. Puchau et al., “Contribution of gender and body fat distribution to inflammatory marker concentrations in apparently healthy young adults,” Inflammation Research, vol. 61, no. 5, pp. 427–435, 2012.
- J. Choi, L. Joseph, and L. Pilote, “Obesity and C-reactive protein in various populations: a systematic review and meta-analysis,” Obesity Reviews. In press.
- J. Naowaboot, P. Pannangpetch, V. Kukongviriyapan, B. Kongyingyoes, and U. Kukongviriyapan, “Antihyperglycemic, antioxidant and antiglycation activities of mulberry leaf extract in streptozotocin-induced chronic diabetic rats,” Plant Foods for Human Nutrition, vol. 64, no. 2, pp. 116–121, 2009.
- W. Naowaratwattana, W. De-Eknamkul, and E. G. De Mejia, “Phenolic-containing organic extracts of mulberry (Morus alba L.) leaves inhibit HepG2 hepatoma cells through G2/M phase arrest and inhibition of topoisomerase IIα activity,” Journal of Medicinal Food, vol. 13, no. 5, pp. 1045–1056, 2010.
- D. M. Vigushin, M. B. Pepys, and P. N. Hawkins, “Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease,” Journal of Clinical Investigation, vol. 91, no. 4, pp. 1351–1357, 1993.
- W. E. Benitz, M. Y. Han, A. Madan, and P. Ramachandra, “Serial serum C-reactive protein levels in the diagnosis of neonatal infection,” Pediatrics, vol. 102, no. 4, p. E41, 1998.
- C. K. Glass and J. L. Witztum, “Atherosclerosis: the road ahead,” Cell, vol. 104, no. 4, pp. 503–516, 2001.
- Z. Guo, H. Van Remmen, H. Yang et al., “Changes in expression of antioxidant enzymes affect cell-mediated LDL oxidation and oxidized LDL-induced apoptosis in mouse aortic cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 7, pp. 1131–1138, 2001.
- D. Lapenna, S. De Gioia, G. Ciofani et al., “Glutathione-related antioxidant defenses in human atherosclerotic plaques,” Circulation, vol. 97, no. 19, pp. 1930–1934, 1998.
- G. L. Milne, E. S. Musiek, and J. D. Morrow, “F2-isoprostanes as markers of oxidative stress in vivo: an overview,” Biomarkers, vol. 10, supplement 1, pp. S10–23, 2005.
- S. Sciascia, D. Roccatello, M. T. Bertero, et al., “8- isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study,” Inflammation Research, vol. 61, no. 8, pp. 809–816, 2012.